Haffner MC, Zwart W, Roudier MP, True LD, Nelson WG, Epstein JI, et al. Genomic and phenotypic heterogeneity in prostate cancer. Nat Rev Urol. 2021;18:79–92.
Schwarz FM, Schniewind I, Besso MJ, Lange S, Linge A, Patil SG et al. Plasticity within aldehyde dehydrogenase-positive cells determines prostate cancer radiosensitivity. Mol Cancer Res MCR. 2022;molcanres.MCR-21-0806-A.2021.
Zattoni F, Marra G, Martini A, Kasivisvanathan V, Grummet J, Harkin T, et al. Is there an impact of Transperineal Versus Transrectal magnetic resonance imaging–targeted Biopsy on the risk of upgrading in final Pathology in prostate Cancer patients undergoing radical prostatectomy? An European Association of Urology-Young Academic urologists prostate Cancer Working Group multi-institutional study. Eur Urol Focus. 2023;9:621–8.
Wu S, Feldman AS, Kim MM, Lin SX, Cornejo KM, Harisinghani MG, et al. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and radical prostatectomy specimens: a comparison of Transperineal and Transrectal approaches. Urology. 2023;175:151–6.
Taggart R, Dutto L, Leung HY, Salji M, Ahmad I. A contemporary analysis of disease upstaging of Gleason 3 + 3 prostate cancer patients after robot-assisted laparoscopic prostatectomy. Cancer Med. 2023;12:20830–7.
Article PubMed PubMed Central Google Scholar
Loeb S, Vellekoop A, Ahmed HU, Catto J, Emberton M, Nam R, et al. Systematic review of complications of prostate biopsy. Eur Urol. 2013;64:876–92.
Zhu X, Shao L, Liu Z, Liu Z, He J, Liu J, et al. MRI-derived radiomics models for diagnosis, aggressiveness, and prognosis evaluation in prostate cancer. J Zhejiang Univ Sci B. 2023;24:663–81.
Article CAS PubMed Google Scholar
Midiri F, Vernuccio F, Purpura P, Alongi P, Bartolotta TV. Multiparametric MRI and Radiomics in prostate Cancer: a review of the current literature. Diagnostics. 2021;11:1829.
Article PubMed PubMed Central Google Scholar
Chaddad A, Kucharczyk MJ, Niazi T. Multimodal Radiomic features for the Predicting Gleason score of prostate Cancer. Cancers. 2018;10:249.
Article PubMed PubMed Central Google Scholar
Shao L, Yan Y, Liu Z, Ye X, Xia H, Zhu X, et al. Radiologist-like artificial intelligence for grade group prediction of radical prostatectomy for reducing upgrading and downgrading from biopsy. Theranostics. 2020;10:10200–12.
Article CAS PubMed PubMed Central Google Scholar
Spohn SKB, Bettermann AS, Bamberg F, Benndorf M, Mix M, Nicolay NH, et al. Radiomics in prostate cancer imaging for a personalized treatment approach - current aspects of methodology and a systematic review on validated studies. Theranostics. 2021;11:8027–42.
Article PubMed PubMed Central Google Scholar
Johnson DC, Raman SS, Mirak SA, Kwan L, Bajgiran AM, Hsu W, et al. Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. Eur Urol. 2019;75:712–20.
Article CAS PubMed Google Scholar
Priester A, Natarajan S, Khoshnoodi P, Margolis DJ, Raman SS, Reiter RE, et al. Magnetic resonance imaging underestimation of prostate Cancer geometry: Use of Patient Specific molds to correlate images with whole Mount Pathology. J Urol. 2017;197:320–6.
Bois F, Noirot C, Dietemann S, Mainta IC, Zilli T, Garibotto V, et al. [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review. Am J Nucl Med Mol Imaging. 2020;10:349–74.
CAS PubMed PubMed Central Google Scholar
Spohn S, Jaegle C, Fassbender TF, Sprave T, Gkika E, Nicolay NH, et al. Intraindividual comparison between 68Ga-PSMA-PET/CT and mpMRI for intraprostatic tumor delineation in patients with primary prostate cancer: a retrospective analysis in 101 patients. Eur J Nucl Med Mol Imaging. 2020;47:2796–803.
Article CAS PubMed PubMed Central Google Scholar
Combes AD, Palma CA, Calopedos R, Wen L, Woo H, Fulham M, et al. PSMA PET-CT in the diagnosis and staging of prostate Cancer. Diagnostics. 2022;12:2594.
Article CAS PubMed PubMed Central Google Scholar
Maitre P, Sood S, Pathare P, Krishnatry R, Agrawal A, Rangarajan V, et al. Timing of Ga68-PSMA PETCT and patterns of recurrence after prostate radiotherapy: implications for potential salvage. Radiother Oncol. 2022;169:71–6.
Article CAS PubMed Google Scholar
Zamboglou C, Spohn SKB, Adebahr S, Huber M, Kirste S, Sprave T, et al. PSMA-PET/MRI-Based focal dose escalation in patients with primary prostate Cancer treated with stereotactic body Radiation Therapy (HypoFocal-SBRT): study protocol of a Randomized, Multicentric Phase III Trial. Cancers. 2021;13:5795.
Article PubMed PubMed Central Google Scholar
Houshmand S, Lawhn-Heath C, Behr S. PSMA PET imaging in the diagnosis and management of prostate cancer. Abdom Radiol N Y. 2023;48:3610–23.
Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, et al. Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference. Theranostics. 2019;9:2595–605.
Article CAS PubMed PubMed Central Google Scholar
Schwarzenboeck SM, Rauscher I, Bluemel C, Fendler WP, Rowe SP, Pomper MG, et al. PSMA ligands for PET imaging of prostate Cancer. J Nucl Med. 2017;58:1545–52.
Article CAS PubMed Google Scholar
Pattison DA, Debowski M, Gulhane B, Arnfield EG, Pelecanos AM, Garcia PL, et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2022;49:763–76.
Article CAS PubMed Google Scholar
Hoberück S, Löck S, Borkowetz A, Sommer U, Winzer R, Zöphel K, et al. Intraindividual comparison of [68 Ga]-Ga-PSMA-11 and [18F]-F-PSMA-1007 in prostate cancer patients: a retrospective single-center analysis. EJNMMI Res. 2021;11:109.
Article PubMed PubMed Central Google Scholar
Woythal N, Arsenic R, Kempkensteffen C, Miller K, Janssen J-C, Huang K, et al. Immunohistochemical Validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate Cancer. J Nucl Med. 2018;59:238–43.
Article CAS PubMed Google Scholar
Vetrone L, Mei R, Bianchi L, Giunchi F, Farolfi A, Castellucci P, et al. Histology and PSMA expression on immunohistochemistry in high-risk prostate Cancer patients: comparison with 68Ga-PSMA PET/CT features in primary staging. Cancers. 2023;15:1716.
Article CAS PubMed PubMed Central Google Scholar
Heetman JG, Hermsen R, Exterkate L, Küsters-Vandevelde HVN, Brouwer LJM, Somford DM, et al. Immunohistochemical and histopathological validation of 18F-PSMA-1007 PET/CT for intraprostatic cancerous lesions. Prostate. 2023;83:1332–41.
Article CAS PubMed Google Scholar
Minner S, Wittmer C, Graefen M, Salomon G, Steuber T, Haese A, et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate. 2011;71:281–8.
Chang SS. Overview of prostate-specific membrane Antigen. Rev Urol. 2004;6:S13–8.
PubMed PubMed Central Google Scholar
Schiller F, Fechter T, Zamboglou C, Chirindel A, Salman N, Jilg CA, et al. Comparison of PET/CT and whole-mount histopathology sections of the human prostate: a new strategy for voxel-wise evaluation. EJNMMI Phys. 2017;4:21.
Article CAS PubMed PubMed Central Google Scholar
Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, et al. MRI versus 68Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43:889–97.
Article CAS PubMed Google Scholar
Cardinale J, Martin R, Remde Y, Schäfer M, Hienzsch A, Hübner S, et al. Procedures for the GMP-Compliant production and Quality Control of [18F]PSMA-1007: a Next Generation Radiofluorinated Tracer for the detection of prostate Cancer. Pharmaceuticals. 2017;10:77.
留言 (0)